|Articles|October 2, 2015
Teva to Buy Leading Mexican Pharma Firm
October 02, 2015.
Advertisement
Teva (Petah Tikva, Israel) has entered into an agreement to acquire Mexican pharma company Representaciones e Investigaciones Médicas (Rimsa) for $2.3 billion,
Rimsa, which had a 2014 revenue of $227 million, has a portfolio of specialty products, including fixed-dose combination products. The company has a 45-year history as one of Mexico's companies; Mexico is the second largest healthcare market in Latin America.
Teva expects to close the transactions by Q1 2016.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal
2
Marty Makary Out as FDA Commissioner: Report
3
The Insight Gap: Biopharma’s Hidden Risk in the Race Against the Patent Cliff
4
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
5